| [1] |
Dondi A, Guida F, Trombetta L, et al. Burden and clinical characteristics of influenza and its complications in children across multiple epidemic seasons[J/OL]. Viruses, 2025, 17(12): 1574. https://doi.org/10.3390/v17121574.
|
| [2] |
Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J/OL]. Lancet, 2018, 391(10127): 1285-1300. https://doi.org/10.1016/S0140-6736(17)33293-2.
|
| [3] |
Zheng Y, He D, Zuo WT, et al. Influenza A virus dissemination and infection leads to tissue resident cell injury and dysfunction in viral sepsis[J/OL]. EBioMedicine, 2025, 116:105738. https://doi.org/10.1016/j.ebiom.2025.105738.
|
| [4] |
Fu C, Huang Q, Zhao J, et al. Clinical characteristics and co-infection analysis of influenza a virus in pediatric respiratory infections: a study based on tNGS technology[J/OL]. Eur J Clin Microbiol Infect Dis, 2025, 44(7): 1695-1704. https://doi.org/10.1007/s10096-025-05143-3.
|
| [5] |
Ma T, Yang C, Wang Y, et al. Cathepsin S contributes to influenza-induced lung injury by driving inflammation, promoting apoptosis, and disrupting epithelial barrier integrity[J/OL]. Microbiol Spectr, 2026, 14(1): e0112825. https://doi.org/10.1128/spectrum.01128-25.
|
| [6] |
Niles MA, Kronhart S, Decker KE, et al. Influenza A virus-induced interferon-alpha production by myeloid dendritic cells and macrophages requires productive infection[J/OL]. Emerg Microbes Infect, 2025, 14(1): 2556718. https://doi.org/10.1080/22221751.2025.2556718.
|
| [7] |
Downey J, Oliveira-Coelho A, Laghlali G, et al. Influenza A virus hijacks monocyte trafficking to damage the heart and impair cardiac function[J/OL]. J Immunol, 2025, 214. https://doi.org/10.1093/jimmun/vkaf283.908.
|
| [8] |
Andersen H, Aid M, Stone JJ, et al. Immunopathogenesis of lethal H5N1 avian influenza virus clade 2.3.4.4b infection in macaques[J/OL]. Immunity, 2025, 58(9): 2157-2165. https://doi.org/10.1016/j.immuni.2025.07.020.
|
| [9] |
Gu J, Yan Y, Zeng Z, et al. Hemagglutinin with a polybasic cleavage site confers high virulence on H7N9 avian influenza viruses[J/OL]. Poult Sci, 2025, 104(2): 104832. https://doi.org/10.1016/j.psj.2025.104832.
|
| [10] |
Wang J, Zhang Y, Sun L, et al. Eukaryotic RNA binding protein hnRNPH1 suppresses influenza A virus replication through interaction with virus NS1 protein[J/OL]. Emerg Microbes Infect, 2025, 14(1): 2477645. https://doi.org/10.1080/22221751.2025.2477645.
|
| [11] |
Aljohani OA, Mackie D, Bratincsak A, et al. Spectrum of viral pathogens identified in children with clinical myocarditis (pre-coronavirus disease-2019, 2000-2018):etiologic agent versus innocent bystander[J/OL]. J Pediatr, 2022, 242: 18-24. https://doi.org/10.1016/j.jpeds.2021.11.011.
|
| [12] |
Zhang L, Liu K, Duan X, et al. CXCL12/CXCR4 axis mediates CD8+ T cell overactivation in the progression of viral myocarditis[J/OL]. J Transl Med, 2025, 23(1): 399. https://doi.org/10.1186/s12967-025-06394-6.
|
| [13] |
Ling I, Steed AL. Pediatric viral myocarditis: mechanisms, experimental models, and research gaps[J/OL]. Pediatr Res, 2026. https://doi.org/10.1038/s41390-026-04845-4.
|
| [14] |
Uyeki TM, Hui DS, Zambon M, et al. Influenza[J/OL]. Lancet, 2022, 400(10353): 693-706. https://doi.org/10.1016/S0140-6736(22)00982-5.
|
| [15] |
Kerr J, Macartney K, Britton PN. Influenza-associated myositis: a single-centre, 5-year retrospective study[J/OL]. Eur J Pediatr, 2021, 180(2): 577-584. https://doi.org/10.1007/s00431-020-03835-w.
|
| [16] |
Turan C, Yurtseven A, Cicek C, et al. Benign acute childhood myositis associated with influenza A/B in the paediatric emergency department and the efficacy of early-onset oseltamivir[J/OL]. J Paediatr Child Health, 2022, 58(6): 1022-1027. https://doi.org/10.1111/jpc.15894.
|
| [17] |
Desdouits M, Munier S, Prevost MC, et al. Productive infection of human skeletal muscle cells by pandemic and seasonal influenza A(H1N1) viruses[J/OL]. PLoS One, 2013, 8(11): e79628. https://doi.org/10.1371/journal.pone.0079628.
|
| [18] |
Influenza-Associated Acute Necrotizing Encephalopathy (IA-ANE) Working Group; Silverman A, Walsh R, et al. Influenza-associated acute necrotizing encephalopathy in US children[J/OL]. JAMA, 2025, 334(8): 692-701. https://doi.org/10.1001/jama.2025.11534.
|
| [19] |
李珊珊, 胡丹丹. 儿童甲型H1N1流行性感冒相关性脑病死亡危险因素分析[J/OL]. 临床儿科杂志, 2025, 43(3): 177-183. https://doi.org/10.12372/jcp.2025.24e0881.
|
|
Li SS, Hu DD. Analysis of risk factors for death from influenza A (H1N1)-associated encephalopathy in children[J/OL]. Linchuang Erke Zazhi, 2025, 43(3): 177-183. https://doi.org/10.12372/jcp.2025.24e0881.
|
| [20] |
Li X, Huang C, Rai KR, et al. Innate immune role of IL-6 in influenza a virus pathogenesis[J/OL]. Front Cell Infect Microbiol, 2025,15:1605446. https://doi.org/10.3389/fcimb.2025.1605446.
|
| [21] |
Geng C, Ju YL, Wang J, et al. The genetic landscape of acute necrotizing encephalopathy: insights into the possible pathogenesis[J/OL]. J Clin Neurol, 2025, 21(4): 340-347. https://doi.org/10.3988/jcn.2025.0061.
|
| [22] |
Sun R, Zhang X, Hou J, et al. Predictive value of IL-6 and lymphocyte subsets for death in children with influenza-associated encephalopathy a retrospective study[J/OL]. Mediators Inflamm, 2024, 2024: 5564727. https://doi.org/10.1155/mi/5564727.
|
| [23] |
Zhang D, Yang Y, Chen Z, et al. High fever, low GCS, and high lactate: independent risk factors for progression of influenza-associated encephalopathy to acute necrotizing encephalopathy in children[J/OL]. BMC Infect Dis, 2025, 25(1): 1424. https://doi.org/10.1186/s12879-025-11833-2.
|
| [24] |
Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2025-2026:technical report[J/OL]. Pediatrics. 2025, 156(6): e2025073622. https://doi.org/10.1542/peds.2025-073622.
|
| [25] |
Gao Y, Zhao Y, Liu M, et al. Antiviral medications for treatment of nonsevere influenza: a systematic review and network meta-analysis[J/OL]. JAMA Intern Med, 2025, 185(3): 293-301. https://doi.org/10.1001/jamainternmed.2024.7193.
|
| [26] |
Ishiguro N, Morioka I, Nakano T, et al. Clinical and virologic outcomes of baloxavir compared with oseltamivir in pediatric patients with influenza in Japan[J/OL]. Infect Dis Ther, 2025, 14(4): 833-846. https://doi.org/10.1007/s40121-025-01131-4.
|
| [27] |
Yan M, Gu X, Wang Y, et al. Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial[J/OL]. Open Forum Infect Dis, 2025, 12(8):ofaf439. PMID:40852135. https://doi.org/10.1093/ofid/ofaf439.
|
| [28] |
Case JR, Khaperskyy DA. Impaired host shutoff is a fitness cost associated with baloxavir marboxil resistance mutations in influenza A virus PA/PA-X nuclease domain[J/OL]. PLoS Pathog, 2026, 22(2): e1013550. https://doi.org/10.1371/journal.ppat.1013550.
|
| [29] |
中华医学会呼吸病学分会,中华医学会感染病学分会. 中国流感治疗与药物预防临床实践指南(2025版)[J/OL]. 中华医学杂志, 2026, 106(2): 122-139.https://doi.org/10.3760/cma.j.cn112137-20251120-03042.
|
|
Chinese Thoracic Society, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Clinical practice guidelines for the treatment and prophylaxis of influenza in China (2025 edition)[J/OL]. Zhonghua Yixue Zazhi, 2026, 106(2): 122-139. https://doi.org/10.3760/cma.j.cn112137-20251120-03042.
|
| [30] |
Seldeslachts L, Kraisin S, Dewi IMW, et al. Anakinra restores immunological misfiring that drives influenza-associated pulmonary aspergillosis[J/OL]. Sci Transl Med, 2025, 17(827): eadw9578. https://doi.org/10.1126/scitranslmed.adw9578.
|
| [31] |
Lei B, Wang S, Yu LZ, et al. Post-influenza bacterial infection: mechanisms of pathogenesis and advances in therapeutic strategies[J/OL]. Front Microbiol, 2025, 16: 1673643. https://doi.org/10.3389/fmicb.2025.1673643.
|
| [32] |
Wang S, Quang Le T, Chida J, et al. Mechanisms of matrix metalloproteinase-9 upregulation and tissue destruction in various organs in influenza A virus infection[J/OL]. J Med Invest, 2010, 57(1-2): 26-34. https://doi.org/10.2152/jmi.57.26.
|
| [33] |
中国疾病预防控制中心. 中国流感疫苗预防接种技术指南(2023-2024)[J/OL]. 中国病毒病杂志, 2024, 14(1): 1-19.
|
|
Chinese Center For Disease Control And Prevention. Technical guidelines for seasonal influenza vaccination in China,2023-2024[J/OL]. Zhongguo Bingdu Zazhi, 2024, 14(1): 1-19. https://doi.org/10.16505/j.2095-0136.2024.1001.
|
| [34] |
流行性感冒诊疗方案(2025年版)[J/OL]. 中国感染控制杂志, 2025, 24(2): 290-294. https://doi.org/10.12138/j.issn.1671-9638.20257379.
|
|
Influenza diagnosis and treatment protocol(2025 Edition)[J/OL]. Zhongguo Ganran Kongzhi Zazhi, 2025, 24(2): 290-294. https://doi.org/10.12138/j.issn.1671-9638.20257379.
|
| [35] |
Frutos AM, Cleary S, Reeves EL, et al. Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness - four vaccine effectiveness networks, United States, October 2024-February 2025[J/OL]. MMWR Morb Mortal Wkly Rep, 2025, 74(6): 83-90. https://doi.org/10.15585/mmwr.mm7406a2.
|
| [36] |
Ferdinands JM, Olsho LE, Agan AA, et al. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012[J/OL]. J Infect Dis, 2014, 210(5): 674-683. https://doi.org/10.1093/infdis/jiu185.
|
| [37] |
贾茹, 马燕, 俞群, 等. 上海市市郊两区16岁以下儿童流感疫苗接种情况及影响因素分析[J]. 临床儿科杂志, 2026, 44(1): 31-37. https://doi.org/10.12372/jcp.2026.25e1162.
|
|
Jia R, Ma Y, Yu Q, et al. An analysis of influenza vaccine coverage and influencing factors among children under 16 years old in two suburban districts of Shanghai[J]. Linchuang Erke Zazhi, 2026, 44(1): 31-37 https://doi.org/10.12372/jcp.2026.25e1162.
|